Ubs Group Ag Sage Therapeutics, Inc. Transaction History

Ubs Group Ag

$400 Billion
Q2 2024

A detailed history of Ubs Group Ag transactions in Sage Therapeutics, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 139,563 shares of SAGE stock, worth $971,358. This represents 0.0% of its overall portfolio holdings.

Number of Shares

139,563

Previous 255,226 45.32%

Holding current value

$971,358

Previous $4.78 Million 68.32%

% of portfolio

0.0%

Previous 0.0%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	SELL	$10.58 - $17.9 $1.22 Million - $2.07 Million	-115,663 Reduced 45.32%	139,563 $1.52 Million
Q1 2024 May 13, 2024	BUY	$18.62 - $26.95 $968,649 - $1.4 Million	52,022 Added 25.6%	255,226 $4.78 Million
Q4 2023 Feb 09, 2024	BUY	$17.1 - $22.26 $1.72 Million - $2.24 Million	100,465 Added 97.79%	203,204 $4.4 Million
Q3 2023 Nov 09, 2023	BUY	$16.75 - $48.98 $374,496 - $1.1 Million	22,358 Added 27.82%	102,739 $2.11 Million
Q2 2023 Aug 11, 2023	BUY	$40.65 - $59.54 $20,243 - $29,650	498 Added 0.62%	80,381 $3.78 Million
Q1 2023 May 12, 2023	SELL	$37.27 - $46.57 $816,063 - $1.02 Million	-21,896 Reduced 21.51%	79,883 $3.35 Million
Q4 2022 Feb 08, 2023	BUY	$32.2 - $43.61 $2.62 Million - $3.55 Million	81,310 Added 397.23%	101,779 $3.88 Million
Q3 2022 Nov 10, 2022	SELL	$32.28 - $43.27 $1.75 Million - $2.35 Million	-54,292 Reduced 72.62%	20,469 $801,000
Q2 2022 Aug 10, 2022	SELL	$27.52 - $37.99 $1.59 Million - $2.19 Million	-57,717 Reduced 43.57%	74,761 $2.42 Million
Q1 2022 May 16, 2022	SELL	$30.71 - $45.71 $51,930 - $77,295	-1,691 Reduced 1.26%	132,478 $4.39 Million
Q4 2021 Feb 14, 2022	BUY	$37.06 - $47.11 $1.34 Million - $1.7 Million	36,169 Added 36.91%	134,169 $5.71 Million
Q3 2021 Nov 15, 2021	BUY	$40.26 - $57.37 $2.85 Million - $4.07 Million	70,887 Added 261.45%	98,000 $4.34 Million
Q2 2021 Aug 13, 2021	SELL	$54.88 - $79.29 $260,240 - $375,993	-4,742 Reduced 14.89%	27,113 $1.54 Million
Q1 2021 May 12, 2021	BUY	$70.65 - $96.76 $1.44 Million - $1.97 Million	20,378 Added 177.56%	31,855 $2.38 Million
Q4 2020 Feb 11, 2021	SELL	$58.41 - $89.06 $606,879 - $925,333	-10,390 Reduced 47.51%	11,477 $993,000
Q3 2020 Nov 12, 2020	SELL	$41.13 - $62.45 $1.59 Million - $2.41 Million	-38,660 Reduced 63.87%	21,867 $1.34 Million
Q2 2020 Jul 31, 2020	BUY	$25.95 - $43.15 $1.19 Million - $1.98 Million	45,934 Added 314.77%	60,527 $2.52 Million
Q1 2020 May 01, 2020	BUY	$26.15 - $77.24 $88,099 - $260,221	3,369 Added 30.02%	14,593 $420,000
Q4 2019 Feb 14, 2020	SELL	$60.18 - $154.77 $359,274 - $923,976	-5,970 Reduced 34.72%	11,224 $810,000
Q3 2019 Nov 14, 2019	SELL	$140.29 - $189.96 $1.42 Million - $1.92 Million	-10,087 Reduced 36.97%	17,194 $2.41 Million
Q2 2019 Aug 14, 2019	SELL	$157.85 - $183.09 $592,095 - $686,770	-3,751 Reduced 12.09%	27,281 $5 Million
Q1 2019 May 14, 2019	SELL	$89.33 - $163.65 $1.41 Million - $2.58 Million	-15,771 Reduced 33.7%	31,032 $4.94 Million
Q4 2018 Feb 14, 2019	BUY	$81.94 - $139.71 $2.19 Million - $3.73 Million	26,726 Added 133.12%	46,803 $4.48 Million
Q3 2018 Nov 14, 2018	BUY	$138.11 - $169.04 $840,261 - $1.03 Million	6,084 Added 43.48%	20,077 $2.84 Million
Q2 2018 Aug 14, 2018	SELL	$140.36 - $175.76 $1.33 Million - $1.67 Million	-9,500 Reduced 40.44%	13,993 $2.19 Million
Q1 2018 May 15, 2018	BUY	$152.15 - $192.33 $2.53 Million - $3.2 Million	16,636 Added 242.61%	23,493 $3.79 Million
Q4 2017 Feb 14, 2018	SELL	$60.72 - $167.34 $771,569 - $2.13 Million	-12,707 Reduced 64.95%	6,857 $1.13 Million
Q3 2017 Nov 14, 2017	BUY	$61.4 - $88.52 $468,666 - $675,673	7,633 Added 63.98%	19,564 $1.22 Million
Q2 2017 Aug 14, 2017	SELL	N/A	-8,810 Reduced 42.48%	11,931 $950,000
Q1 2017 Nov 14, 2017	BUY	N/A	20,741	20,741 $1.48 Million

Others Institutions Holding SAGE

# of Institutions

217

Shares Held

48.2M

Call Options Held

854K

Put Options Held

195K

View Full List

About Sage Therapeutics, Inc.

Ticker SAGE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,422,300
Market Cap $414M
Description
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...

More about SAGE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account